The fund is a new $125M fund jointly founded by a New York-based firm and a Korea-based firm in 2021. The New York based firm is a global investment banking and strategic advisory firm specialized in life sciences, with decades of experience in supporting multiple leading life science companies. The Korea-based firm is a subsidiary of a leading Korean venture capital firm with over 30 years of investment experience. The firm seeks to invest between $2-10M (over the company’s lifespan) in therapeutics and medical device companies, with its sweet spot being Series A financings. The firm is actively sourcing deals globally with a focus on USA.

The fund seeks to invest 80% in therapeutics and 20% in medical devices. Indication-wise, the firm is most interested in oncology, CNS, cardiovascular, and rare diseases. The firm expects companies to already be conducting IND enabling studies or are currently running clinical trials. The firm will consider all types of modalities. The firm also has a broad interest in all types of medical devices, from traditional devices to cell therapy equipment, and will consider devices of all regulatory pathways including 510k and PMA.

The fund has no specific company or management team requirements. The firm is open to leading, co-leading, and co-investing, and will seek board representation when they act as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

An early-stage VC fund founded in 2011 by a group of alumni from Tsinghua University is based in Los Altos, California. The group currently has $100M, under management. The group focuses on Angel to Series B stage companies across various sectors, including pharmaceutical, medical device, services and tools, and digital health. The typical investment size is between $1M to $2M. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe.

The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed rounds and series A rounds. Historically, the fund has been active in life science companies developing innovative platform technologies and cross-disciplinary technologies.

The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Founded in 1973, a private equity firm headquartered in Tokyo, Japan. The firm has additional offices in Palo Alto, Singapore, Hong Kong, Taipei, Beijing, Shanghai, and Seoul. The firm has about JPY 980 billion AUM (~USD 9.1 billion). The firm is currently making new investments from three main funds: SV6 Series (JPY 75 billion; 2019 vintage), Asia Technology Fund VII (USD 140 million; 2017), and Icon Ventures V (USD 260 million; 2012). The firm has a dedicated life science investment team and invests in venture stage companies. The firm invests in various stages, typically start-up and early stage. For life science companies, the firm generally allocates USD 3-5 million per round. The firm is currently focused on opportunities in the US, Israel, and Japan.

The firm invests opportunistically in the life sciences. The firm seeks to invest in innovative therapeutics, diagnostics, and medical devices. For therapeutics, the firm generally invests in novel platform technologies and considers both small molecules and biologics. The firm is indication agnostic and will consider orphan diseases. The firm is also agnostic to the stage of development, but typically invests in companies with a lead asset in clinical trials. For medical devices, the firm is also opportunistic and generally invests in devices that are in the clinic. The firm generally only invests in new IP/NCEs, and does not invest in repurposed or reformulated products.

The firm is currently focused on private companies in the US, Israel and Japan. The firm generally requires a seat on the board of directors or observers.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The venture arm of a global advisory dedicated to healthcare with practices across regulatory and clinical affairs, market access and His EOR strategy consulting, and investment banking. The firm uses its experience in the industry to invest in promising early-stage companies developing medical devices, diagnostics or digital health technologies. The firm invests at the seed stage, and serves as a strategic investor as much as a financial investor, using industry knowledge and contacts to help companies grow. The firm will generally invest between $250K-1M in companies that have some proof of concept and IP. The firm will invest globally.

The firm invests in medical device, diagnostics and digital health companies. While the firm is generally agnostic to subsector and indication, it tends to avoid companies with a long time to exit. In addition, while the firm is willing to consider all types of medical devices, they are less likely to invest in PMA devices at this stage.

The firm is a very active investor, and thus takes a board seat, even if just an observer position, to lend their expertise. The firm can lead or coinvest, but tends to coinvest, and can help build a syndicate with their contacts.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.